Market Cap : 471.53 M | Enterprise Value : 444.25 M | PE Ratio : 18.55 | PB Ratio : 9.36 |
---|
NAS:CODX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CODX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Co-Diagnostics's gross profit for the three months ended in Sep. 2020 was $16.00 Mil. Co-Diagnostics's gross profit for the trailing twelve months (TTM) ended in Sep. 2020 was $35.19 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Co-Diagnostics's gross profit for the three months ended in Sep. 2020 was $16.00 Mil. Co-Diagnostics's Revenue for the three months ended in Sep. 2020 was $21.82 Mil. Therefore, Co-Diagnostics's Gross Margin % for the quarter that ended in Sep. 2020 was 73.32%.
Co-Diagnostics had a gross margin of 73.32% for the quarter that ended in Sep. 2020 => Durable competitive advantage
During the past 5 years, the highest Gross Margin % of Co-Diagnostics was 77.50%. The lowest was 47.91%. And the median was 62.71%.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Co-Diagnostics's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Co-Diagnostics's Gross Profit for the fiscal year that ended in Dec. 2019 is calculated as
Gross Profit (A: Dec. 2019 ) | = | Revenue | - | Cost of Goods Sold |
= | 0.215 | - | 0.112 | |
= | 0.10 |
Co-Diagnostics's Gross Profit for the quarter that ended in Sep. 2020 is calculated as
Gross Profit (Q: Sep. 2020 ) | = | Revenue | - | Cost of Goods Sold |
= | 21.819 | - | 5.821 | |
= | 16.00 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2020 was 0.056 (Dec. 2019 ) + 1.067 (Mar. 2020 ) + 18.065 (Jun. 2020 ) + 15.997 (Sep. 2020 ) = $35.19 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Co-Diagnostics's Gross Margin % for the quarter that ended in Sep. 2020 is calculated as
Gross Margin % (Q: Sep. 2020 ) | = | Gross Profit (Q: Sep. 2020 ) | / | Revenue (Q: Sep. 2020 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 16.00 | / | 21.819 | |
= | 73.32 % |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Co-Diagnostics had a gross margin of 73.32% for the quarter that ended in Sep. 2020 => Durable competitive advantage
No Headline